{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:45:15Z","timestamp":1760060715310,"version":"build-2065373602"},"reference-count":45,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Agency for Medical Research and Development (AMED)","award":["JP25am0521010","JP25ama121008","JP25ama221339","JP25bm1123027","25K10553"],"award-info":[{"award-number":["JP25am0521010","JP25ama121008","JP25ama221339","JP25bm1123027","25K10553"]}]},{"name":"Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI)","award":["JP25am0521010","JP25ama121008","JP25ama221339","JP25bm1123027","25K10553"],"award-info":[{"award-number":["JP25am0521010","JP25ama121008","JP25ama221339","JP25bm1123027","25K10553"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>CD44 variants (CD44v) play essential roles in the promotion of tumor metastasis, maintenance of cancer stem cell properties, and resistance to treatments. Therefore, the development of anti-CD44v mAbs is essential for targeting CD44v-positive tumor cells. An anti-CD44v9 mAb, C44Mab-1 (mouse, IgG1, kappa), was previously established. C44Mab-1 recognizes the variant exon 9-encoded region and applies to multiple research techniques. A mouse IgG2a version of C44Mab-1 (C44Mab-1-mG2a) was generated to evaluate the in vitro and in vivo antitumor activities using gastric and colorectal cancer cell lines. C44Mab-1-mG2a showed a reactivity to CD44v3\u201310-overexpressed Chinese hamster ovary-K1 (CHO\/CD44v3\u201310), gastric cancer MKN45, and colorectal cancer COLO205 in flow cytometry. C44Mab-1-mG2a exhibited both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CHO\/CD44v3\u201310, MKN45, and COLO205. Furthermore, administration of C44Mab-1-mG2a significantly suppressed CHO\/CD44v3\u201310, MKN45, and COLO205 xenograft tumor growth compared with control mouse IgG2a. These results indicated that C44Mab-1-mG2a, which possesses ADCC\/CDC activities, could be applied to the mAb-based therapy against CD44v9-positive carcinomas.<\/jats:p>","DOI":"10.3390\/ijms26189170","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T12:08:03Z","timestamp":1758542883000},"page":"9170","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antitumor Activity by an Anti-CD44 Variant 9 Monoclonal Antibody in Gastric and Colorectal Cancer Xenograft Models"],"prefix":"10.3390","volume":"26","author":[{"given":"Mayuki","family":"Tawara","sequence":"first","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5132","authenticated-orcid":false,"given":"Hiroyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9039-4474","authenticated-orcid":false,"given":"Tomokazu","family":"Ohishi","sequence":"additional","affiliation":[{"name":"Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4158-9208","authenticated-orcid":false,"given":"Mika K.","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-8201","authenticated-orcid":false,"given":"Yukinari","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0092-8674(89)90638-7","article-title":"A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family","volume":"56","author":"Stamenkovic","year":"1989","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","article-title":"CD44: From adhesion molecules to signalling regulators","volume":"4","author":"Ponta","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1083\/jcb.124.1.71","article-title":"Expression and modulation of CD44 variant isoforms in humans","volume":"124","author":"Mackay","year":"1994","journal-title":"J. Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/10408360290795574","article-title":"CD44 in cancer","volume":"39","author":"Naor","year":"2002","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc3023","article-title":"CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule?","volume":"11","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.matbio.2006.08.261","article-title":"Hyaluronan-mediated angiogenesis in vascular disease: Uncovering RHAMM and CD44 receptor signaling pathways","volume":"26","author":"Slevin","year":"2007","journal-title":"Matrix Biol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Hassn Mesrati, M., Syafruddin, S.E., Mohtar, M.A., and Syahir, A. (2021). CD44: A Multifunctional Mediator of Cancer Progression. Biomolecules, 11.","DOI":"10.3390\/biom11121850"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1111\/febs.16179","article-title":"The state of CD44 activation in cancer progression and therapeutic targeting","volume":"289","author":"Guo","year":"2021","journal-title":"FEBS J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.biocel.2016.09.009","article-title":"CD44: More than a mere stem cell marker","volume":"81 Pt A","author":"Morath","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1083\/jcb.128.4.687","article-title":"CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor","volume":"128","author":"Bennett","year":"1995","journal-title":"J. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1101\/gad.242602","article-title":"CD44 is required for two consecutive steps in HGF\/c-Met signaling","volume":"16","author":"Chen","year":"2002","journal-title":"Genes. Dev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2011.01.038","article-title":"CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(\u2212) and thereby promotes tumor growth","volume":"19","author":"Ishimoto","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"34876","DOI":"10.18632\/oncotarget.26172","article-title":"High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy","volume":"9","author":"Kagami","year":"2018","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wang, Z., Tang, Y., Xie, L., Huang, A., Xue, C., Gu, Z., Wang, K., and Zong, S. (2019). The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00309"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Durko, L., Wlodarski, W., Stasikowska-Kanicka, O., Wagrowska-Danilewicz, M., Danilewicz, M., Hogendorf, P., Strzelczyk, J., and Malecka-Panas, E. (2017). Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis. Dis. Markers, 2017, Correction in Dis. Markers 2017, 2017, 9617615.","DOI":"10.1155\/2017\/3276806"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1007\/s11033-019-05058-1","article-title":"Markers of pancreatic cancer stem cells and their clinical and therapeutic implications","volume":"46","author":"Gzil","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"65143","DOI":"10.18632\/oncotarget.17821","article-title":"CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.canlet.2019.10.010","article-title":"CD44(+) tumor cells promote early angiogenesis in head and neck squamous cell carcinoma","volume":"467","author":"Ludwig","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/2159-8290.CD-18-0065","article-title":"Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models","volume":"9","author":"Liu","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mesrati, M.H., Behrooz, A.B., Abuhamad, A.Y., and Syahir, A. (2020). Understanding Glioblastoma Biomarkers: Knocking a Mountain with a Hammer. Cells, 9.","DOI":"10.3390\/cells9051236"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11432","DOI":"10.1073\/pnas.1914294117","article-title":"A mode of cell adhesion and migration facilitated by CD44-dependent microtentacles","volume":"117","author":"Wolf","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.3390\/cimb45040238","article-title":"A Novel Anti-CD44 Variant 9 Monoclonal Antibody C44Mab-1 Was Developed for Immunohistochemical Analyses against Colorectal Cancers","volume":"45","author":"Tawara","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kaneko, M.K., Suzuki, H., Ohishi, T., Nakamura, T., Tanaka, T., and Kato, Y. (2024). A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031941"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Goto, N., Suzuki, H., Tanaka, T., Asano, T., Kaneko, M.K., and Kato, Y. (2022). Development of a Novel Anti\u2212CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105535"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00204-014-1424-2","article-title":"Perspectives of CD44 targeting therapies","volume":"89","author":"Ponta","year":"2015","journal-title":"Arch. Toxicol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"80046","DOI":"10.18632\/oncotarget.11098","article-title":"First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors","volume":"7","author":"Coveler","year":"2016","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.oraloncology.2007.10.009","article-title":"Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma","volume":"44","author":"Riechelmann","year":"2008","journal-title":"Oral. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","article-title":"A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus","volume":"12","author":"Tijink","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1111\/cas.15353","article-title":"CD44v3,8-10 is essential for Slug-dependent vimentin gene expression to acquire TGF-\u03b21-induced tumor cell motility","volume":"113","author":"Qiu","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ando, T., Yamasaki, J., Saya, H., and Nagano, O. (2025). CD44: A key regulator of iron metabolism, redox balance, and therapeutic resistance in cancer stem cells. Stem Cells, 43.","DOI":"10.1093\/stmcls\/sxaf024"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/bjc.2013.314","article-title":"CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence","volume":"109","author":"Hirata","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10120-016-0610-8","article-title":"Dose-escalation study for the targeting of CD44v(+) cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)","volume":"20","author":"Shitara","year":"2017","journal-title":"Gastric Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 513, 202\u2013209.","DOI":"10.1038\/nature13480"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0002-9440(10)65297-2","article-title":"Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway","volume":"154","author":"Wielenga","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1242\/jcs.90.1.145","article-title":"Distribution of hyaluronate and hyaluronate receptors in the adult lung","volume":"90","author":"Green","year":"1988","journal-title":"J. Cell Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1083\/jcb.146.4.843","article-title":"Analysis of CD44-containing lipid rafts: Recruitment of annexin II and stabilization by the actin cytoskeleton","volume":"146","author":"Oliferenko","year":"1999","journal-title":"J. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1158\/1541-7786.MCR-06-0384","article-title":"A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression","volume":"5","author":"Kuhn","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Porcellini, S., Asperti, C., Corna, S., Cicoria, E., Valtolina, V., Stornaiuolo, A., Valentinis, B., Bordignon, C., and Traversari, C. (2020). CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00099"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/mab.2023.0033","article-title":"Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H2Mab-250\/H2CasMab-2 for Breast Cancers","volume":"43","author":"Kaneko","year":"2024","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.stem.2025.05.007","article-title":"Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy","volume":"32","author":"Hosking","year":"2025","journal-title":"Cell Stem Cell"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kudo, Y., Suzuki, H., Tanaka, T., Kaneko, M.K., and Kato, Y. (2023). Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody C44Mab-3 for Multiple Applications against Pancreatic Carcinomas. Antibodies, 12.","DOI":"10.20944\/preprints202301.0581.v1"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ishikawa, K., Suzuki, H., Ohishi, T., Nakamura, T., Yanaka, M., Li, G., Tanaka, T., Ohkoshi, A., Kawada, M., and Kaneko, M.K. (2024). Antitumor activities of anti-CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer. Oncol. Rep., 52.","DOI":"10.3892\/or.2024.8806"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Li, G., Suzuki, H., Ohishi, T., Asano, T., Tanaka, T., Yanaka, M., Nakamura, T., Yoshikawa, T., Kawada, M., and Kaneko, M.K. (2023). Antitumor activities of a defucosylated anti-EpCAM monoclonal antibody in colorectal carcinoma xenograft models. Int. J. Mol. Med., 51.","DOI":"10.3892\/ijmm.2023.5221"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/9170\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:00Z","timestamp":1760035560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/9170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":45,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26189170"],"URL":"https:\/\/doi.org\/10.3390\/ijms26189170","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}